Resistance to Aromatase Inhibitors in Breast Cancer

1. Front Matter

   Pages i-xvi

   PDF

2. Clinical Use of Aromatase Inhibitors in Breast Cancer: History and Present

   • David Cameron

   Pages 1-11

3. Structure, Regulation and Polymorphisms of the Aromatase Gene

   • Nobuhiro Harada

   Pages 13-31

4. Structure, Function and Inhibition of Aromatase

   • Debashis Ghosh, Jessica Lo, Chinaza Egbuta

   Pages 33-61

5. In Vivo Models of AI Resistance

   • Gauri Sabnis, Angela Brodie

   Pages 63-86

6. Ineffective Inhibition of Aromatase: A Cause for AI Resistance?

   • Per E. Lønning

   Pages 87-99

7. Understanding the New Biology of Estrogen-Induced Apoptosis and Its Application in Patient Care

   • Elizabeth E. Sweeney, V. Craig Jordan

   Pages 101-114

8. Ligand-Independent Signalling Through Estrogen Receptor Pathways in Breast Cancer

   • Jean McBryan, Leonie S. Young

   Pages 115-144

9. Chromatin and Epigenetic Determinants of Resistance to Aromatase Inhibitors

   • Raffaella Maria Gadaleta, Luca Magnani

   Pages 145-168

10. Aromatase Inhibitor Resistance via Non-endocrine Signalling Pathways

    • Abdul Aziz Bin Aiderus, Anita K. Dunbier

    Pages 169-190

11. Prediction of Response to Aromatase Inhibitors in Breast Cancer

    • Alexey A. Larionov, William R. Miller

    Pages 191-228

12. Clinical Trials Combining Aromatase Inhibitors with Other Targeted Treatments

    • Hazel Lote, Stephen Johnston

    Pages 229-259

13. Aromatase Inhibitors Beyond Breast Cancer: Endometrium Versus Breast Puzzle and Other Issues

    • Lev M. Berstein

    Pages 261-285

14. Back Matter

    Pages 287-288

    PDF

Aromatase Inhibitors (AIs) treat postmenopausal estrogen receptor positive tumours, which constitute the majority of breast cancer patients. This comprehensive volume brings together the current knowledge from different relevant areas, including molecular mechanisms and translational aspects of drug resistance in AIs. Topics covered include research, experimental , and clinical data specifically focused on AI resistance in breast cancer. The volume will include three sections. The first section covers general knowledge about aromatase inhibitors, including regulation of aromatase genes, and structure and function of aromatase protein. The second section provides the detailed mechanisms of resistance to AIs, while the third section explores prediction of resistance and potential strategies to overcome resistance. Breast cancer is the most common female cancer and AIs significantly improve treatments outcomes compatibly to previously used endocrine treatments. However 10-15% of post-operative patients develop a relapse during adjuvant treatment with AIs; about 25-50% of the patients do not respond to AIs in neo-adjuvant or metastatic setting, and the majority of metastatic patients who initially respond develop resistance within 3 years. There is an important need to understand these mechanisms of resistance in order to develop methods of preventing or overcoming the resistance to AIs, which will ensure a more successful outcome in treating breast cancer.

• aromatase protein
• breast cancer
• estrogen receptor
• genetic polymorphism
• oestrogens
• antibacterial drug resistance

• Academic Laboratory of Medical Genetics, School of Clinical Medicine, Cancer Research UK Cambridge Institute, Statistics and Computational Biology Laboratory & University of Cambridge, Cambridge, United Kingdom

  Alexey Larionov

Alexey Larionov, Ph.D. is a researcher at the Academic Laboratory of Medical Genetics and Statistics and Computational Biology Lab at the University of Cambridge. Dr Larionov is an expert in endocrine resistance in breast cancer, as well as whole exome sequencing data analysis. Dr. Larionov has received over 1019 citations.

Policies and ethics